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Importance: Multiple studies conducted in the general population identified an
association between self-reported coffee consumption and plasma lipid levels. To date,
no study assessed whether and which plasma methylxanthines (caffeine and/or its
metabolites, i.e., paraxanthine, theophylline, and theobromine) are associated with
plasma lipids. In psychiatric patients, an important coffee consumption is often reported
and many psychotropic drugs can induce a rapid and substantial increase of plasma lipid
levels.
Objective: To determine whether plasmamethylxanthines are associatedwithmetabolic
parameters in psychiatric patients receiving treatments known to induce metabolic
disturbances.
Design, Setting, and Participants: Data were obtained from a prospective study
including 630 patients with metabolic parameters [i.e., body mass index (BMI), total
cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein
cholesterol (HDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and fasting
triglycerides (TG)] monitored routinely during psychotropic treatment.
Exposures: Plasma methylxanthines levels.
Main Outcomes and Measures: Metabolic variables including BMI and plasma lipid
levels.
Delacrétaz et al. Caffeine and Lipid Levels in Psychiatric Patients
Results: Multivariate analyses indicated that BMI, TC, HDL-C, and non-HDL-C
increased significantly with increasing total methylxanthines (pcorrected ≤ 0.05). In
addition, compared to patients with plasma caffeine concentration in the lowest quartile,
those with caffeine concentration in the highest quartile were twice more prone to suffer
from non-HDL hypercholesterolemia (pcorrected = 0.05), five times more likely to suffer
from hypertriglyceridemia (pcorrected = 0.01) and four times more susceptible to be
overweight (pcorrected = 0.01).
Conclusions and Relevance: This study showed that plasma caffeine and
other methylxanthines are associated with worsening of metabolic parameters in
patients receiving psychotropic treatments known to induce metabolic disturbances. It
emphasizes that important caffeine consumption could be considered as an additional
environmental risk factor for metabolic worsening in patients receiving such treatments.
Keywords: psychotropic drugs, lipids, plasma caffeine level, plasma methylxanthines, metabolic parameters,
secondary effects
INTRODUCTION
Coffee is one of the most commonly consumed beverages
worldwide and its influence on multiple human health features
has been extensively demonstrated (1). A large body of
epidemiological studies has examined the association of coffee
consumption with various diseases, often yielding inconsistent
results. Recent reviews integrating numerous meta-analyses
have drawn comprehensive conclusions on the overall effects
of coffee consumption. In particular, one recent umbrella
review, i.e., a review gathering existing research syntheses
of different outcomes for the same intervention, showed
that coffee consumption has beneficial effects on a broad
range of chronic diseases including cancers, neurological
diseases, and cardiovascular diseases (2). However, potential
detrimental effects of caffeine consumption on certain health
outcomes were also reported, as for instance on serum
lipids.
For the last 30 years, multiple epidemiological studies
considering association between coffee consumption and
serum lipids resulted in inconsistent findings (3–18). More
recently, a meta-analysis identified significant positive
associations between coffee consumption and serum lipid
levels in population-based cohorts, despite an important
heterogeneity among considered studies (19). Thus, on average,
drinking coffee for 45 days was associated with significant
increases of total cholesterol (TC), low-density lipoprotein
cholesterol (LDL-C), and triglyceride (TG) of 8.1 mg/dl (0.21
mmol/l), 5.4 mg/dl (0.14 mmol/l), and 12.6 mg/dl (0.14
mmol/l), respectively (19). Interestingly, a dose-response
influence of coffee intake on serum lipid levels was recognized,
suggesting that the influence of caffeine and/or other coffee
components on blood lipid levels may be dose-dependent.
Consistent with this hypothesis, methylxanthines including
caffeine and its metabolites (i.e., paraxanthine, theobromine,
and theophylline) were related with multiple biological
effects such as an increased fat oxidation, mobilization of
glycogen in muscle as well as an increased lipolysis (20, 21).
However, methylxanthines are found in many other widespread-
consumed products than coffee (e.g., tea, energy drinks, and
chocolate) (22) and their concentration in coffee is highly
variable (23). Thus, as previous studies all considered self-
reported coffee consumption to evaluate the influence of
caffeine and of other methylxanthines on various outcomes
of interest, the observed effects may not have been sufficiently
accurate.
In psychiatric patients, an important coffee consumption
has been reported (24), and higher rates of high caffeine
consumers were observed in psychiatric patients compared
to individuals from the general population (25–27), which
may enhance the risk of developing hyperlipidemia. Sedative
and/or anticholinergic effects induced by psychotropic drugs
may constitute one possible argument to explain a higher
coffee consumption in psychiatric patients than in the
general population. In addition, the use of psychotropic
medications such as antipsychotics (most atypical but also
some typical), mood stabilizers (e.g., lithium and valproate),
and some antidepressants (e.g., mirtazapine) can increase
the risk of developing metabolic disorders including obesity
and dyslipidemia (28–31). These factors, combined with
additional risk factors including psychiatric disease-related
factors, unhealthy lifestyle, and poverty (32, 33), may therefore
contribute to the excessive susceptibility of psychiatric patients
for developing cardiovascular diseases.
To the best of our knowledge, no study has yet investigated
whether plasma methylxanthine levels are associated with
plasma lipid levels and body mass index (BMI), neither
in the general nor in the psychiatric population. In the
present study, we measured plasma levels of caffeine and
its metabolites in a large cohort of psychiatric patients
receiving psychotropic treatments known to induce
metabolic disturbances, aiming to examine whether plasma
methylxanthine levels are associated with lipid parameters and
BMI.
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METHODS
Study Design
Since 2007, a longitudinal observational study (PsyMetab)
has been ongoing at the Department of Psychiatry of the
Lausanne University Hospital as described elsewhere (34).
Patients with informed consent starting or already receiving a
psychotropic treatment known to have a potential risk to induce
metabolic disturbances (i.e., antipsychotics, mood stabilizers, and
some antidepressants, as listed in S1 Table) were included, as
described in the flowchart (S1 Figure). More information in
Supplementary Material.
Lipid and Methylxanthine Parameters
The majority of blood samples (i.e., 66%) were drawn in
fasting conditions. Non-fasting blood samples (i.e., within
6 h following last meal) were excluded only for triglyceride
analysis (not for total, HDL- and LDL-cholesterol) (35, 36).
LDL-cholesterol was calculated using the Friedewald
formula only if triglyceride levels were lower than 3.5
mmol/l (37, 38). In the present study, dyslipidemia was
defined as hypercholesterolemia (TC ≥ 5 mmol/l) and/or
HDL hypocholesterolemia (HDL-C < 1 mmol/l) and/or
LDL hypercholesterolemia (LDL-C ≥ 3 mmol/l) and/or
hypertriglyceridemia (TG ≥ 2 mmol/l) and/or if patients were
treated with lipid-lowering drugs (S2 Table). More information
on quantification of lipids and of methylxanthines (i.e., caffeine,
paraxanthine, theophylline, and theobromine) is available in
Supplementary Material.
Statistical Analyses
Wilcoxon-Mann-Whitney rank-sum tests and Chi-squared tests
were conducted to compare continuous and categorical variables,
respectively, across patient groups (e.g., patients stratified by
methylxanthine quartiles). Plasma levels of methylxanthine
were log-transformed to reduce their variability. The xtmixed
procedure in Stata 14 was used to fit linear mixed effect models
on plasma lipid levels adjusting for age, sex, smoking status,
psychotropic medication, treatment duration, BMI (whenever
appropriate), and plasma methylxanthine levels. The fitted
linear mixed effect model had a random effect at the subject
level.
In order to determine whether and which stratified
analyses could be conducted, statistical interactions of
possible confounding factors [i.e., age, gender, smoking
status, psychotropic medication, treatment duration, and BMI
(or TC whenever applicable)] with methylxanthine levels on
metabolic outcomes (i.e., lipid levels and BMI) were tested by
including interaction terms in linear mixed models adjusting for
covariates.
Odds ratio of disturbed metabolic outcomes (e.g.,
dyslipidemia and overweight) by quartiles of plasma
methylxanthines were conducted using logistic mixed effects
models adjusting for age, sex, smoking status, psychotropic
medication, treatment duration, and BMI or TC, whenever
applicable.
Statistical significance was defined as a p-value ≤ 0.05.
P-values were adjusted for multiple testing using the false
discovery rate (FDR) approach. Statistical analyses were
performed using Stata 14 (StataCorp, College Station TX,
USA) and R environment for statistical computing version
3.3.1.
RESULTS
Demographics and Plasma Levels of Lipids
and Methylxanthines
Demographic and clinical characteristics of the psychiatric
sample are displayed in Table 1. Six hundred and thirty patients
without missing data were included. Median age was 39 years
[interquartile range (IQR): 27–54], psychotic disorders (F20–F24;
F28; F29) were the most frequent diagnosis (49%) and quetiapine
was the most frequently prescribed psychotropic drug (29%).
Half of the patients smoked (50%) and 70% of the selected
observation for each single patient was collected within the first 6
months of treatment.
The evolution of metabolic parameters and of methylxanthine
plasma levels during treatment with psychotropic drugs is
presented in S3 Table and in Table 2, respectively. Although
patients might differ across periods of treatment, a significant
worsening of TC, LDL-C, and non-HDL-C levels occurred
during treatment with psychotropic drugs. Thus, TC, LDL-C
levels, and non-HDL-C increased from 4.8, 2.8, and 3.4 mmol/l
at baseline to 5.1, 3.0, and 3.7 mmol/l after 6 months of
treatment (p = 0.02, 0.03, and 0.01), respectively. Of note, no
significant worsening was observed for HDL-C or TG, possibly
attributable to an insufficient power due to the lower number
of observations and/or to a lower variation of these parameters.
Interestingly, plasma levels of total methylxanthines increased
significantly during treatment with psychotropic drugs (pcorrected
≤ 0.05).
Methylxanthines increased significantly with increasing age
(pcorrected ≤ 0.005, S4 Table and S2 Figure) except theobromine.
S4 Table shows that women were more prone to have high
levels of all methylxanthines but theobromine (pcorrected ≤
0.04). More interestingly, BMI and all plasma lipid levels but
LDL-C significantly increased with increasing quartiles of all
methylxanthines (pcorrected ≤ 0.05), except for theobromine.
S3.1–S3.6 Figures display distribution of plasma lipid levels
and of BMI according to plasma levels of methylxanthines. In
accordance with results from methylxanthine quartiles analyses,
BMI, and plasma levels of TC, LDL-C, TG, and non-HDL-C
increased with increasing levels of methylxanthines, while the
association between HDL-C and methylxanthine levels was
less apparent. Of note, prevalence of hypercholesterolemia and
overweight increased significantly with increasing quartiles of all
methylxanthines but theobromine (pcorrected ≤ 0.04; S5 Table).
S6 Table shows that neither diagnosis nor psychotropic
medication groups were associated with methylxanthine levels.
Finally, trends of higher levels of methylxanthines except
theobromine were observed in patients receiving clozapine
or olanzapine [i.e., drugs with high concomitant affinities for
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TABLE 1 | Demographic parameters and plasma levels of lipids and of
methylxanthines in patients receiving psychotropic drugs.
Total
n = 630
Male, n (%) 327 (51.9)
Age, median (IQR) (years) 39 (27–54)
Main diagnosis, n (%)
Organic mental disorders (F0) 14 (3.0)
Psychotic disorders (F20–F24, F28, F29) 232 (48.8)
Schizoaffective disorders (F25) 48 (10.1)
Bipolar disorders (F30–F31) 83 (17.5)
Depressive disorders (F32–F33) 98 (20.6)
Psychotropic medication, n (%)
Amisulpride 60 (9.5)
Aripiprazole 61 (9.7)
Asenapine 1 (0.2)
Clozapine 32 (5.1)
Haloperidol 2 (0.3)
Lithium 36 (5.7)
Lurasidone 1 (0.2)
Mirtazapine 21 (3.3)
Olanzapine 92 (14.6)
Quetiapine 181 (28.7)
Risperidone 130 (20.6)
Valproate 12 (1.9)
Zuclopenthixol 1 (0.2)
Smoking, n (%)
Yes 314 (49.8)
No 316 (50.2)
Duration of psychotropic treatment, n (%) (months)
Baseline 62 (9.8)
1 227 (36.0)
2–5 152 (24.1)
≥6 189 (30.0)
Total cholesterol, median (IQR) (mmol/l) (n = 630) 5.0 (4.3–5.7)
LDL-C, median (IQR) (mmol/l) (n = 602) 2.9 (2.3–3.6)
HDL-C, median (IQR) (mmol/l) (n = 623) 1.4 (1.1–1.6)
Fasting TG, median (IQR) (mmol/l) (n = 424) 1.2 (0.9–1.8)
Non-HDL-C, median (IQR) (mmol/l) (n = 623) 3.6 (2.9–4.4)
BMI, median (IQR) (kg/m2) (n = 630) 24.2 (21.5–28.4)
Caffeine, median (IQR) (ng/ml) 416 (84–1,513)
Paraxanthine, median (IQR) (ng/ml) 507 (164–1,178)
Theophylline, median (IQR) (ng/ml) 75 (31–174)
Theobromine, median (IQR) (ng/ml) 626 (256–1,301)
Total methylxanthines, median (IQR) (ng/ml) 2,002 (805–4,195)
Patients with available age, sex, smoking status, psychotropic medication, treatment
duration, BMI and plasma levels of lipids and of methylxanthines, and who did not receive
any lipid lowering treatment were included in analyses. Only the first observation per
patient was included. IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol;
HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; non-HDL-C, non-high-
density lipoprotein cholesterol; BMI, body mass index.
AchM and H1 receptors (39)] as compared to patients who
received drugs with less potent anticholinergic and sedative
effects (pcorrected = 0.06, S7 Table). T
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TABLE 3 | Adjusted median of plasma lipid levels according to quartiles of methylxanthine levels.
Lipid variables Quartile 1 Quartile 2 Quartile 3 Quartile 4 pa
corrected
LOG CAFFEINE
Total cholesterol, median (IQR) (mmol/l) 4.8 (4.6–5.1) 4.9 (4.6–5.2) 5.1 (4.8–5.4) 5.2 (5–5.5) 0.02
LDL cholesterol, median (IQR) (mmol/l) 2.9 (2.7–3.1) 2.9 (2.7–3.2) 3 (2.8–3.3) 3.1 (2.9–3.3) 0.71
HDL cholesterol, median (IQR) (mmol/l) 1.3 (1.2–1.5) 1.3 (1.2–1.5) 1.4 (1.3–1.5) 1.4 (1.3–1.6) 0.001
Fasting triglyceride, median (IQR) (mmol/l) 1.3 (1–1.5) 1.4 (1.2–1.7) 1.5 (1.2–1.7) 1.5 (1.3–1.8) 0.15
NonHDL cholesterol, median (IQR) (mmol/l) 3.5 (3.2–3.8) 3.6 (3.3–3.9) 3.7 (3.4–4) 3.8 (3.5–4.1) 0.11
BMI, median (IQR) (kg/m2) 24.6 (24.2–25.1) 25.4 (24.9–25.9) 25.7 (25.2–26.2) 25.9 (25.4–26.3) 0.003
LOG PARAXANTHINE
Total cholesterol, median (IQR) (mmol/l) 4.8 (4.6–5.1) 4.9 (4.7–5.2) 5 (4.7–5.3) 5.3 (5.1–5.6) 0.006
LDL cholesterol, median (IQR) (mmol/l) 2.9 (2.7–3.1) 3 (2.8–3.2) 2.9 (2.7–3.2) 3.2 (3–3.4) 0.71
HDL cholesterol, median (IQR) (mmol/l) 1.3 (1.2–1.6) 1.3 (1.2–1.5) 1.4 (1.3–1.6) 1.5 (1.3–1.6) 0.001
Fasting triglyceride, median (IQR) (mmol/l) 1.3 (1–1.5) 1.5 (1.3–1.8) 1.5 (1.2–1.7) 1.5 (1.3–1.7) 0.47
NonHDL cholesterol, median (IQR) (mmol/l) 3.4 (3.2–3.7) 3.6 (3.4–4) 3.6 (3.3–4) 3.9 (3.6–4.1) 0.11
BMI, median (IQR) (kg/m2) 24.7 (24.2–25.2) 25.3 (24.8–25.8) 25.6 (25.1–26.1) 25.9 (25.4–26.4) 0.004
LOG THEOPHYLLINE
Total cholesterol, median (IQR) (mmol/l) 4.7 (4.5–5) 5 (4.8–5.3) 5 (4.8–5.3) 5.3 (5.1–5.5) 0.005
LDL cholesterol, median (IQR) (mmol/l) 2.8 (2.6–3) 3 (2.8–3.3) 3 (2.7–3.2) 3.1 (2.9–3.4) 0.71
HDL cholesterol, median (IQR) (mmol/l) 1.3 (1.2–1.5) 1.3 (1.2–1.4) 1.4 (1.3–1.6) 1.4 (1.3–1.6) 0.001
Fasting triglyceride, median (IQR) (mmol/l) 1.3 (1–1.5) 1.4 (1.2–1.7) 1.5 (1.2–1.7) 1.6 (1.3–1.8) 0.08
NonHDL cholesterol, median (IQR) (mmol/l) 3.4 (3.1–3.7) 3.7 (3.4–4) 3.7 (3.3–4) 3.8 (3.6–4.1) 0.04
BMI, median (IQR) (kg/m2) 24.6 (24.1–25.1) 25.3 (24.8–25.9) 25.8 (25.2–26.2) 25.9 (25.5–26.4) <0.001
LOG THEOBROMINE
Total cholesterol, median (IQR) (mmol/l) 4.9 (4.7–5.1) 5 (4.7–5.3) 5 (4.7–5.3) 5.1 (4.8–5.4) 0.005
LDL cholesterol, median (IQR) (mmol/l) 2.9 (2.7–3.1) 3 (2.8–3.3) 3 (2.8–3.3) 3 (2.8–3.2) 0.71
HDL cholesterol, median (IQR) (mmol/l) 1.3 (1.2–1.5) 1.3 (1.2–1.5) 1.4 (1.3–1.6) 1.4 (1.3–1.6) 0.003
Fasting triglyceride, median (IQR) (mmol/l) 1.4 (1.1–1.7) 1.4 (1.2–1.7) 1.4 (1.2–1.6) 1.5 (1.2–1.8) 0.46
NonHDL cholesterol, median (IQR) (mmol/l) 3.5 (3.3–3.8) 3.7 (3.4–4) 3.6 (3.3–3.9) 3.7 (3.4–4) 0.05
BMI, median (IQR) (kg/m2) 24.8 (24.3–25.3) 25.6 (25.1–26.1) 25.5 (25.1–26.1) 25.5 (25–26) 0.03
LOG TOTAL METHYLXANTHINE
Total cholesterol, median (IQR) (mmol/l) 4.8 (4.6–5.1) 5.0 (4.7–5.3) 5 (4.7–5.3) 5.3 (5.1–5.6) 0.005
LDL cholesterol, median (IQR) (mmol/l) 2.9 (2.7–3.1) 3 (2.8–3.2) 3 (2.7–3.2) 3.1 (2.9–3.3) 0.71
HDL cholesterol, median (IQR) (mmol/l) 1.3 (1.2–1.5) 1.3 (1.2–1.5) 1.4 (1.3–1.6) 1.4 (1.3–1.6) <0.001
Fasting triglyceride, median (IQR) (mmol/l) 1.3 (1–1.5) 1.4 (1.2–1.7) 1.4 (1.1–1.7) 1.6 (1.3–1.9) 0.08
NonHDL cholesterol, median (IQR) (mmol/l) 3.5 (3.2–3.7) 3.6 (3.3–4) 3.6 (3.3–3.9) 3.9 (3.6–4.1) 0.05
BMI, median (IQR) (kg/m2) 24.7 (24.1–25.2) 25.5 (25–26.1) 25.5 (25–26) 25.8 (25.3–26.3) 0.004
Patients with available age, sex, smoking status, psychotropic medication, treatment duration, BMI and plasma levels of lipids and of methylxanthines, and who did not receive any lipid
lowering treatment were included in the analyses. Linear mixed regression adjusting for age, sex, smoking status, psychotropic drug group, treatment duration and BMI were fitted for
630 patients (n observations = 1,272).
a p-values for linear trend are reported. Linearity of association was verified. FDR correction was applied. Values in bold are significant.
Log caffeine: Q1:≤4.43 ng/ml; Q2: >4.43–≤6.03 ng/ml; Q3: >6.03–≤7.32 ng/ml; Q4 >7.32 ng/ml; Log paraxanthine: Q1:≤5.1 ng/ml; Q2: >5.1–≤6.23 ng/ml; Q3: >6.23–≤7.07 ng/ml;
Q4 >7.07 ng/ml; Log theophylline: Q1: ≤3.43 ng/ml; Q2: >3.43–≤4.31 ng/ml; Q3: >4.31–≤5.16 ng/ml; Q4 >5.16 ng/ml; Log theobromine: Q1: ≤5.55 ng/ml; Q2: >5.55–≤6.44 ng/ml;
Q3: >6.44–≤7.17 ng/ml; Q4 >7.17 ng/ml; Log total methylxanthine: Q1: ≤6.69 ng/ml; Q2: >6.69–≤7.6 ng/ml; Q3: >7.6–≤8.34 ng/ml; Q4 >8.34 ng/ml.
Associations of Plasma Methylxanthines
With Metabolic Parameters
Multivariate analyses adjusting for previously mentioned
covariates indicated significant associations between plasma
methylxanthines and metabolic parameters (S8 Table). In
particular, each of the four methylxanthines and their sum (i.e.,
caffeine, paraxanthine, theophylline, theobromine, and total
methylxanthines) were positively associated with TC, HDL-C,
and BMI (pcorrected ≤ 0.02, ≤ 0.02, and ≤ 0.02, respectively), but
not with LDL-C and TG. In addition, non-HDL-C was positively
associated with all methylxanthines except caffeine (pcorrected
≤ 0.05). More information are in Supplementary Material.
Further adjusted analyses considering methylxanthine quartiles
indicated similar findings, showing significant differences of
metabolic variables across methylxanthine quartiles (Table 3). In
particular, BMI, TC, HDL-C, and non-HDL-C) were significantly
increased with increasing total methylxanthine levels (pcorrected
≤ 0.05). As shown in Figures 1A–C, the odds of displaying
non-HDL hypercholesterolemia, hypertriglyceridemia, and
overweight was more than doubled for patients in the highest
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FIGURE 1 | (A) Odds ratio of non-HDL hypercholesterolemia (i.e., abnormal levels of plasma non-HDL cholesterol) by quartiles of plasma methylxanthines. Quartile 1
was considered as the reference. Odds ratio were adjusted for age, sex, smoking status, psychotropic medication, treatment duration and BMI. 95 CI: 95%
confidence interval. 90 CI: 90% confidence interval. White diamonds represent estimates of adjusted odd ratio. Log caffeine: Q1: ≤4.43 ng/ml; Q2:
>4.43–≤6.03 ng/ml; Q3: >6.03–≤7.32 ng/ml; Q4: >7.32 ng/ml; Log paraxanthine: Q1: ≤5.1 ng/ml; Q2: >5.1–≤6.23 ng/ml; Q3: >6.23–≤7.07 ng/ml; >7.07 ng/ml;
Log theophylline: Q1: ≤3.43 ng/ml; Q2: >3.43–≤4.31 ng/ml; Q3: >4.31–≤5.16 ng/ml; Q4: >5.16 ng/ml; Log theobromine: Q1: ≤5.55 ng/ml; Q2:
>5.55–≤6.44 ng/ml; Q3: >6.44–≤7.17 ng/ml; Q4: >7.17 ng/ml; Log total methylxanthine: Q1: ≤6.69 ng/ml; Q2: >6.69–≤7.6 ng/ml; Q3: >7.6–≤8.34 ng/ml; Q4:
(Continued)
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FIGURE 1 | >8.34 ng/ml. Non-HDL hypercholesterolemia was defined as plasma levels of total cholesterol ≥4 mmol/l, according to ESH/ESC guidelines. (B) Odds
ratio of hypertriglyceridemia by quartiles of plasma methylxanthines. Quartile 1 was considered as the reference. Odds ratio (95% CI) were adjusted for age, sex,
smoking status, psychotropic medication, treatment duration, and BMI. 95 CI: 95% confidence interval. 90 CI: 90% confidence interval. White diamonds represent
estimates of adjusted odd ratio. Log caffeine: Q1: ≤4.43 ng/ml; Q2: >4.43–≤6.03 ng/ml; Q3: >6.03–≤7.32 ng/ml; Q4: >7.32 ng/ml; Log paraxanthine: Q1:
≤5.1 ng/ml; Q2: >5.1–≤6.23 ng/ml; Q3: >6.23–≤7.07 ng/ml; >7.07 ng/ml; Log theophylline: Q1: ≤3.43 ng/ml; Q2: >3.43–≤4.31 ng/ml; Q3: >4.31–≤5.16 ng/ml;
Q4: >5.16 ng/ml; Log theobromine: Q1: ≤5.55 ng/ml; Q2: >5.55–≤6.44 ng/ml; Q3: >6.44–≤7.17 ng/ml; Q4: >7.17 ng/ml; Log total methylxanthine: Q1:
≤6.69 ng/ml; Q2: >6.69–≤7.6 ng/ml; Q3: >7.6–≤8.34 ng/ml; Q4: >8.34 ng/ml. Hypertriglyceridemia was defined as plasma levels of triglyceride ≥2 mmol/l,
according to ESH/ESC guidelines. Only patients in fasting conditions were considered in these analyses. (C) Odds ratio of overweight by quartiles of plasma
methylxanthines. Quartile 1 was considered as the reference. Odds ratio (95% CI) were adjusted for age, sex, smoking status, psychotropic medication, treatment
duration and total cholesterol levels. 95 CI: 95% confidence interval. 90 CI: 90% confidence interval. White diamonds represent estimates of adjusted odd ratio. Log
caffeine: Q1: ≤4.43 ng/ml; Q2: >4.43–≤6.03 ng/ml; Q3: >6.03–≤7.32 ng/ml; Q4: >7.32 ng/ml; Log paraxanthine: Q1: ≤5.1 ng/ml; Q2: >5.1–≤6.23 ng/ml; Q3:
>6.23–≤7.07 ng/ml; >7.07 ng/ml; Log theophylline: Q1: ≤3.43 ng/ml; Q2: >3.43–≤4.31 ng/ml; Q3: >4.31–≤5.16 ng/ml; Q4: >5.16 ng/ml; Log theobromine: Q1:
≤5.55 ng/ml; Q2: >5.55–≤6.44 ng/ml; Q3: >6.44–≤7.17 ng/ml; Q4: >7.17 ng/ml; Log total methylxanthine: Q1: ≤6.69 ng/ml; Q2: >6.69–≤7.6 ng/ml; Q3:
>7.6–≤8.34 ng/ml; Q4: >8.34 ng/ml. Overweight was defined as body mass index ≥25 kg/m2.
quartile of plasma methylxanthines as compared to those in the
lowest quartile (pcorrected ≤ 0.05, pcorrected ≤ 0.03, and pcorrected ≤
0.047, respectively). In particular, compared to patients with
caffeine concentration in the lowest quartile, those with caffeine
concentration in the highest quartile were twice more likely to
display non-HDL hypercholesterolemia (pcorrected = 0.05), five
times more likely to display hypertriglyceridemia (pcorrected =
0.01) and four times more prone to be overweight (pcorrected =
0.01).
Interaction tests were conducted to determine whether
any demographic or clinical variable interacted with plasma
methylxanthines on metabolic parameters (i.e., on plasma lipid
levels and/or on BMI) in order to recognize which stratified
analyses would be beneficial. Analyses on plasma lipid levels
reported no significant interaction between gender, smoking
status, psychotropic treatment duration or psychotropic
treatment category, and methylxanthine concentration on lipids,
suggesting that stratification by these four variables would
not provide additional information and that the association
between methylxanthine levels and metabolic parameters
appears to be similar across categories of these four variables
(S9 Table). However, age and BMI interacted significantly
with methylxanthines on plasma lipid levels and smoking
interacted significantly with methylxanthines on BMI (S9 Table;
S4 Figure). More information are in Supplementary Material.
DISCUSSION
In the present sample of psychiatric patients, plasma levels of
methylxanthines followed an asymmetric right-handed curve,
with a small proportion of patients (approximatively half of
patients in the fourth quartile, corresponding to around 1/8
of all patients) having particularly elevated methylxanthine
concentrations. This right-skewed distribution is in accordance
with an observational study conducted in similar settings
showing that 13% of psychiatric patients presented a markedly
high coffee consumption (24). In the present study, distribution
of methylxanthines from blood samples collected in non-fasting
conditions was similar than those from blood sample drawn in
fasting conditions (data not shown). This suggests that the fasting
status did not influence blood levels of methylxanthines.
In accordance with previous studies, metabolic parameters
including lipid levels and BMI worsened significantly during
treatment with psychotropic drugs (33, 40, 41). In parallel,
plasma levels of methylxanthines increased during psychotropic
treatment, in accordance with a study suggesting that caffeine
consumption may be related to increased thirst due to
anticholinergic effects of certain psychotropic drugs (42).
In addition, further analyses in the present sample showed
that patients receiving drugs with important sedative and
anticholinergic effects [i.e., drugs with high concomitant affinities
for AchM and H1 receptors, namely clozapine and olanzapine
(39)] tended to have higher levels of methylxanthines except
theobromine as compared to patients who received drugs with
less potent anticholinergic and sedative effects. These findings
support the hypothesis of an increased coffee consumption to
overcome sedative effects and/or an increased thirst.
The main finding of the present study is that metabolic
parameters including BMI and plasma lipid levels were positively
associated with plasma levels of methylxanthines in multivariate
analyses adjusting for possible confounding variables. These
results are consistent with secondary findings from a recent
large population-based study on arterial stiffness, showing
increased metabolic parameters (i.e., BMI and plasma lipid
levels) with increasing quartiles of methylxanthines (43). In
addition, our results are in accordance with themost recentmeta-
analysis evaluating association between coffee consumption
and lipid levels, which recognized that, in general population-
based cohorts, drinking coffee was associated on average with
significant increase of lipid levels (e.g., TC by 0.21 mmol/l) (19).
This influence was possibly attributable to biological effects of
caffeine (e.g., increased fat oxidation and an increased lipolysis)
(20). Of note, in the present study and in agreement with
a previous study in the general population (43), increasing
quartiles of methylxanthines were associated with higher levels
of beneficial cholesterol (i.e., HDL-C). Because TC, TG,
and non-HDL-C levels increased to the same extent with
increasing methylxanthine quartiles, it seems unlikely that the
cardiovascular advantage provided by increased HDL-C levels
would counteract detrimental influence of the three other
lipid parameters (i.e., TC, TG, and non-HDL-C). Concerning
the present positive association between methylxanthine levels
and BMI, recent reviews evaluating the influence of coffee
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consumption on metabolic outcomes observed conflicting
results, i.e., that coffee consumption and caffeine intake are
associated with a decreased risk for metabolic syndrome (2, 44).
Possible mechanisms to explain this reduced risk include that
caffeine decreases body weight by increasing energy expenditure
(45), and that this molecule induces changes in the structure
of gut microbiota (i.e., a decreased Firmicutes to Bacteroidetes
ratio), in favor of an anti-obesity profile (46). On the other
hand, a recent mendelian randomization study suggested that
high caffeine intake is causally associated with high BMI and
contrariwise with a lower risk of obesity (47). Thus, the
association between methylxanthine levels, BMI, and obesity is
still controversial and results from previous studies emphasize
the need of future studies to better understand mechanisms
underlying these associations.
Plasma levels of methylxanthines increased with the patients’
age and reached a plateau around 50 years of age, underlying
the importance of considering age as a confounding variable
in multivariate analyses. These findings are consistent with
population-based studies showing that caffeine intake is
age-dependent (48, 49) and with another study showing that the
maximum number of cups of coffee per person per day reaches
a plateau between 30 and 59 years old (50). In the present study,
theobromine levels remained stable across age, showing similar
concentrations between teenagers and adults. As coffee intake
in teenager individuals was reported to be lower than in adults
(42), elevated theobromine concentrations in young patients
may be attributed to consumption of other products than coffee,
including chocolate foods and beverages, which provide low
caffeine but constitute the major source of dietary theobromine
(51). Moreover, theobromine accounts for only 7–8% of caffeine
metabolism (52, 53) and in the present study, the calculated
theobromine/caffeine ratio was close to 1, further supporting
that the present plasma levels of theobromine result from other
sources than from caffeine metabolism exclusively.
Several interactions were observed between methylxanthines
and some clinical variables on metabolic parameters (i.e.,
on plasma lipid levels and on BMI). For instance, age and
BMI interacted significantly with some methylxanthines on
some lipid phenotypes, showing that the association between
plasma methylxanthines and plasma lipid levels was exclusively
applicable in young and lean patients. These findings are
consistent with previous studies showing that young and lean
patients have a greater risk to develop metabolic side effects
than older and heavier patients and that clinical and/or genetic
susceptibilities are more easily revealed in these patients than in
other patients (33, 34, 54). In the present study, another relevant
interaction was observed: positive associations between plasma
methylxanthines and BMI were restricted to non-smoking
patients. This finding is consistent with another study evaluating
the association between caffeine intake and hypertension that
reported an influence of caffeine on hypertension in non-
smokers but not in smokers (55). One hypothesis to explain
this restrictive association is that by inducing CYP1A2 [i.e.,
the main enzyme responsible for caffeine metabolism (56)],
smoking alters plasma concentrations of methylxanthines and
may blind the association between methylxanthines and lipid
levels. In addition, smoking has been shown to stimulate fat
metabolism (57), which can have an impact on BMI and
suppress the contribution of methylxanthines on this metabolic
variable.
Interestingly, most of our positive findings involved caffeine
as well as other methylxanthines (i.e., paraxanthine and
theophylline) but not theobromine. These results are in
accordance with recent findings (43) and can be partly attributed
to the fact that theobromine is less active than caffeine. Thus,
theobromine has two- to three-fold lower affinity than caffeine
for adenosine receptors A1 and A2A (58) and penetrates the
blood-brain barrier less readily than caffeine (59).
Results of the present study should be considered with the
following limitations. First, although this study was longitudinal,
no link of causality could be drawn between methylxanthines
and metabolic parameters. Mendelian randomization analyses
would be a valuable approach to evaluate causality. However,
much larger sample sizes (typically ≥ 10,000 participants) are
required for such analyses (60). Future studies including a higher
number of participants should therefore be conducted in order
to better understand these associations. Second, although most
important factors were considered in the present study, biological
half-life of caffeine varies among individuals and is determined
by multiple genetic, physiological, and environmental factors
(61) that we could not take into account. In addition, time
elapsed between the last consumption of caffeine products and
the blood draw was not available, which may have increased the
variability of methylxanthine levels. However, methylxanthine
levels measured at distinct periods of psychotropic treatment in
similar individuals were comparable. In addition, considering the
sum of all methylxanthines allowed us to take into account inter-
individual differences in caffeine metabolism. It must also be
mentioned that the present study has been performed in patients
receiving psychotropic treatment known to induce metabolic
disturbances and the results are therefore not necessarily valid in
non-treated psychiatric patients or in patients treated with drugs
with no metabolic effects. Strengths of the present study include
its naturalistic setting and its relatively large sample size. In
addition, plasma levels of methylxanthine were measured instead
of using self-reported caffeine consumption, which enhances
accuracy of our results.
In conclusion, the present study showed that plasma levels of
methylxanthines are positively associated with lipids and BMI
in patients receiving psychotropic treatment known to induce
metabolic disturbances. In such patients, caffeine consumption
could therefore be an additional environmental risk factor that
may further worsen their metabolic condition, especially in
young patients who are particularly vulnerable to metabolic
side effects. However, further research is needed to better
understand how the detrimental effect of caffeine on lipids
elevation may be counteracted by its beneficial effect on HDL-
C. In addition, studies in patients who receive psychotropic
treatment inducing metabolic abnormalities and who warrant
specific attention (e.g., young patients with elevated coffee
consumption) should be initiated to determine whether dietary
advices on gradual diminution of coffee consumption should
improve their cardiometabolic health.
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